Solaris Energy Infrastructure will replace Catalyst Pharmaceuticals in the S&P SmallCap 600 ahead of July 15, 2026, per S&P Dow Jones Indices. CPRX is being removed as Angelini Pharma's acquisition of Catalyst closes, a development that could weigh on CPRX near term while SEI may see improved liquidity from index inclusion.
Removal from a benchmark index often prompts selling by index funds or ETFs, creating near-term downside pressure. The CPRX move is tied to an acquisition, but until closing, the stock may face volatility and reduced float as funds adjust to the new composition.
CPRX may face near-term pressure ahead of the July 15 rebalancing, with potential upside if the acquisition closes.
Category fits Corporate Developments with a connected M&A component; index reconstitution is a material liquidity/price driver for small-cap names like CPRX, especially when a deal is ongoing.